Monoclonal Antibodies in Immunodiagnosis and Immunotherapy最新文献_第8页

A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG_2a-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers. 一种去聚焦的小鼠抗cd10单克隆抗体(31-mG2a-f)在小鼠肾细胞癌异种移植模型中发挥抗肿瘤活性

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2021.0049

Hiroki Kawabata, Tomokazu Ohishi, Hiroyuki Suzuki, Teizo Asano, Manabu Kawada, Hiroyoshi Suzuki, Mika K Kaneko, Yukinari Kato

{"title":"A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG2a-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers.","authors":"Hiroki Kawabata, Tomokazu Ohishi, Hiroyuki Suzuki, Teizo Asano, Manabu Kawada, Hiroyoshi Suzuki, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2021.0049","DOIUrl":"https://doi.org/10.1089/mab.2021.0049","url":null,"abstract":"CD10 is a cell surface metalloendopeptidase that cleaves and degrades many secreted physiologically active peptides by its enzymatic activity. Although CD10 expression has been found in various types of cells, its expression is increased in several cancers, including renal cancer. In this study, the antitumor activity of a novel anti-human CD10 monoclonal antibody (mAb) was investigated. A defucosylated mouse IgG2a version of C10Mab-31 (31-mG2a-f) was created from an anti-CD10 mAb, C10Mab-31 (IgG1, kappa). Both C10Mab-31 and 31-mG2a-f specifically reacted with endogenous CD10 in renal cancer cells, VMRC-RCW, with the dissociation constant (KD) values of 6.3 × 10-9 M and 1.1 × 10-9 M, respectively, indicating high binding affinity. To further examine the anti-CD10 mAb-mediated effector functions, the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) were examined. The 31-mG2a-f significantly exhibited ADCC and CDC against VMRC-RCW cells in vitro. Furthermore, 31-mG2a-f exhibited antitumor activities in mouse xenografts of VMRC-RCW cells. These results suggest that 31-mG2a-f exerts antitumor activities against CD10-expressing renal cancers and could be a valuable therapeutic candidate for treating them.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"41 6","pages":"320-327"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10797966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Development of a Novel Anti-Mouse CCR6 Monoclonal Antibody (C₆Mab-13) by N-Terminal Peptide Immunization. 新型抗小鼠CCR6单克隆抗体(C6Mab-13)的n端肽免疫制备

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2022.0021

Teizo Asano, Tomohiro Tanaka, Hiroyuki Suzuki, Guanjie Li, Ren Nanamiya, Nami Tateyama, Yu Isoda, Yuki Okada, Hiyori Kobayashi, Takeo Yoshikawa, Mika K Kaneko, Yukinari Kato

{"title":"Development of a Novel Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) by N-Terminal Peptide Immunization.","authors":"Teizo Asano, Tomohiro Tanaka, Hiroyuki Suzuki, Guanjie Li, Ren Nanamiya, Nami Tateyama, Yu Isoda, Yuki Okada, Hiyori Kobayashi, Takeo Yoshikawa, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2022.0021","DOIUrl":"https://doi.org/10.1089/mab.2022.0021","url":null,"abstract":"The CC chemokine receptor 6 (CCR6) is a G protein-coupled receptor family member that is highly expressed in B lymphocytes, certain subsets of effector and memory T cells, and immature dendritic cells. CCR6 has only one chemokine ligand, CCL20. The CCL20-CCR6 axis has been recognized as a therapeutic target for autoimmune diseases and tumor. This study developed specific monoclonal antibodies (mAbs) against mouse CCR6 (mCCR6) using the peptide immunization method. The established anti-mCCR6 mAb, C6Mab-13 (rat IgG1, kappa), reacted with mCCR6-overexpressed Chinese hamster ovary-K1 (CHO/mCCR6), and mCCR6-endogenously expressed P388 (mouse lymphoid neoplasma) and J774-1 (mouse macrophage-like) cells in flow cytometry. The dissociation constant (KD) of C6Mab-13 for CHO/mCCR6 cells was determined to be 2.8 × 10-9 M, indicating that C6Mab-13 binds to mCCR6 with high affinity. In summary, C6Mab-13 is useful for detecting mCCR6-expressing cells through flow cytometry.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"41 6","pages":"343-349"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10799060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

What Can We Learn from Research with Monoclonal Antibody 1F7? 从单克隆抗体1F7的研究中我们可以学到什么?

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2022.0003

Heinz Kohler

引用次数: 0

Can Endemic Human Coronaviruses Be a COVID-19 Vaccine Approach? 地方性人类冠状病毒可以作为COVID-19疫苗的方法吗?

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2022.29012.editorial

Thomas Kieber-Emmons

引用次数: 0

Development of an Anti-Mouse CCR8 Monoclonal Antibody (C₈Mab-1) for Flow Cytometry and Immunocytochemistry. 用于流式细胞术和免疫细胞化学的抗小鼠CCR8单克隆抗体(C8Mab-1)的研制

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2021.0069

Masaki Saito, Hiroyuki Suzuki, Tomohiro Tanaka, Teizo Asano, Mika K Kaneko, Yukinari Kato

{"title":"Development of an Anti-Mouse CCR8 Monoclonal Antibody (C8Mab-1) for Flow Cytometry and Immunocytochemistry.","authors":"Masaki Saito, Hiroyuki Suzuki, Tomohiro Tanaka, Teizo Asano, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2021.0069","DOIUrl":"https://doi.org/10.1089/mab.2021.0069","url":null,"abstract":"It has been widely accepted that monoclonal antibody (mAb) is an effective tool for cancer immunotherapy. The C-C motif chemokine receptor 8 (CCR8) is highly expressed in regulatory T cells and many cancers and is associated with the progression of the cancers. However, its role in cancer progression remains unclear. Thus, the development of mAbs for CCR8 leads to cancer immunotherapy and elucidation of unknown mechanisms of CCR8-dependent cancer progression. In this study, we have developed an anti-mouse CCR8 (mCCR8) mAb (clone C8Mab-1, rat IgG2a, kappa) using the Cell-Based Immunization and Screening (CBIS) method. We showed that C8Mab-1 and its recombinant antibody (recC8Mab-1) bind to mCCR8-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/mCCR8), but not to the parental CHO-K1 cells, in flow cytometry and immunofluorescence. Moreover, C8Mab-1 and recC8Mab-1 specifically reacted to P388 (a mouse lymphocyte-like cells) and J774-1 (a mouse macrophage-like cells), which express endogenous mCCR8, in both applications. These results suggest that C8Mab-1, developed using the CBIS method, is useful for flow cytometry and immunocytochemistry against exogenous and endogenous mCCR8.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"41 6","pages":"333-338"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10797964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Development of Monoclonal Antibody 281-mG_2a-f Against Golden Hamster Podoplanin. 抗金仓鼠Podoplanin单克隆抗体281-mG2a-f的制备

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2021.0058

Ren Nanamiya, Hiroyuki Suzuki, Junko Takei, Guanjie Li, Nohara Goto, Hiroyuki Harada, Masaki Saito, Tomohiro Tanaka, Teizo Asano, Mika K Kaneko, Yukinari Kato

{"title":"Development of Monoclonal Antibody 281-mG2a-f Against Golden Hamster Podoplanin.","authors":"Ren Nanamiya, Hiroyuki Suzuki, Junko Takei, Guanjie Li, Nohara Goto, Hiroyuki Harada, Masaki Saito, Tomohiro Tanaka, Teizo Asano, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2021.0058","DOIUrl":"https://doi.org/10.1089/mab.2021.0058","url":null,"abstract":"Golden (Syrian) hamster (Mesocricetus auratus) is a small animal model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Pathological analyses of the tissues are required to understand the pathogenesis of SARS-CoV-2 and the evaluation of therapeutic modalities, including neutralizing monoclonal antibodies (mAbs). However, mAbs that recognize the golden hamster-derived antigens and distinguish specific cell types, such as the pneumocytes, are limited. Podoplanin (PDPN) is an essential marker of lung type I alveolar epithelial cells, kidney podocytes, and lymphatic endothelial cells. In this study, an anti-Chinese hamster (Cricetulus griseus) PDPN mAb PMab-281 (IgG3, kappa) was established using the Cell-Based Immunization and Screening (CBIS) method. A defucosylated mouse IgG2a version of PMab-281 (281-mG2a-f) was also developed. The 281-mG2a-f strongly recognized both the Chinese hamster and the golden hamster PDPN using flow cytometry and could detect lung type I alveolar epithelial cells, lymphatic endothelial cells, and Bowman's capsules in the kidney from the golden hamster using immunohistochemistry. These results suggest the usefulness of 281-mG2a-f for analyzing the golden hamster-derived tissues and cells for SARS-CoV-2 research.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"41 6","pages":"311-319"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10797967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Development of a Sensitive Anti-Human CCR9 Monoclonal Antibody (C₉Mab-11) by N-Terminal Peptide Immunization. n端肽免疫制备抗人CCR9敏感单克隆抗体(C9Mab-11)

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2022.0027

Tomohiro Tanaka, Hiroyuki Suzuki, Yu Isoda, Teizo Asano, Takuro Nakamura, Miyuki Yanaka, Saori Handa, Nozomi Takahashi, Saori Okuno, Takeo Yoshikawa, Guanjie Li, Ren Nanamiya, Nohara Goto, Nami Tateyama, Yuki Okada, Hiyori Kobayashi, Mika K Kaneko, Yukinari Kato

{"title":"Development of a Sensitive Anti-Human CCR9 Monoclonal Antibody (C9Mab-11) by N-Terminal Peptide Immunization.","authors":"Tomohiro Tanaka, Hiroyuki Suzuki, Yu Isoda, Teizo Asano, Takuro Nakamura, Miyuki Yanaka, Saori Handa, Nozomi Takahashi, Saori Okuno, Takeo Yoshikawa, Guanjie Li, Ren Nanamiya, Nohara Goto, Nami Tateyama, Yuki Okada, Hiyori Kobayashi, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2022.0027","DOIUrl":"https://doi.org/10.1089/mab.2022.0027","url":null,"abstract":"The C-C chemokine receptor 9 (CCR9) belongs to the G-protein-coupled receptor superfamily, and is highly expressed on the T cells and intestinal cells. CCR9 regulates various immune responses by binding to the C-C chemokine ligand, CCL25, and is involved in inflammatory diseases and tumors. Therefore, the development of sensitive monoclonal antibodies (mAbs) for CCR9 is necessary for treatment and diagnosis. In this study, we established a specific anti-human CCR9 (hCCR9) mAb; C9Mab-11 (mouse IgG2a, kappa), using the synthetic peptide immunization method. C9Mab-11 reacted with hCCR9-overexpressed Chinese hamster ovary-K1 (CHO/hCCR9) and hCCR9-endogenously expressed MOLT-4 (human T-lymphoblastic leukemia) cells in flow cytometry. The dissociation constant (KD) of C9Mab-11 for CHO/hCCR9 and MOLT-4 cells were determined to be 1.2 × 10-9 M and 4.9 × 10-10 M, respectively, indicating that C9Mab-11 possesses a high affinity for both exogenously and endogenously hCCR9-expressing cells. Furthermore, C9Mab-11 clearly detected hCCR9 protein in CHO/hCCR9 cells using western blot analysis. In summary, C9Mab-11 can be a useful tool for analyzing hCCR9-related biological responses.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":"41 6","pages":"303-310"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10818553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A Monoclonal Antibody Targeting C-Terminal Domain of Transmissible Gastroenteritis Virus Spike Protein. 一种靶向传染性胃肠炎病毒刺突蛋白c端结构域的单克隆抗体。

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-12-01 DOI: 10.1089/mab.2022.0030

Na Liu, Yaoming Li

引用次数: 0

KLMab-1: An Anti-human KLRG1 Monoclonal Antibody for Immunocytochemistry. KLMab-1:用于免疫细胞化学的抗人KLRG1单克隆抗体

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-10-01 DOI: 10.1089/mab.2022.0016

Masaki Saito, Hiroyuki Suzuki, Teizo Asano, Tomohiro Tanaka, Takeo Yoshikawa, Mika K Kaneko, Yukinari Kato

{"title":"KLMab-1: An Anti-human KLRG1 Monoclonal Antibody for Immunocytochemistry.","authors":"Masaki Saito, Hiroyuki Suzuki, Teizo Asano, Tomohiro Tanaka, Takeo Yoshikawa, Mika K Kaneko, Yukinari Kato","doi":"10.1089/mab.2022.0016","DOIUrl":"https://doi.org/10.1089/mab.2022.0016","url":null,"abstract":"Immune checkpoint molecules have received attention as targets of cancer immunotherapy. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) is one of the immune checkpoint molecules expressed in CD4+ T, CD8+ T, and natural killer (NK) cells. KLRG1 exhibits antiviral and antitumor immunity, and its expression in T and NK cells is upregulated by viral infectious diseases and some tumors. Thus, monoclonal antibodies (mAbs) for KLRG1 would be useful tools for the diagnosis and immunotherapy against viral infectious diseases and cancers. We have developed anti-human KLRG1 (hKLRG1) mAb (clone KLMab-1, mouse IgG1, kappa) by the Cell-Based Immunization and Screening method. We have also demonstrated that KLMab-1 recognizes both exogenous and endogenous hKLRG1 in flow cytometry. In this study, we first showed that KLMab-1 and its recombinant mAb (recKLMab-1) bound to exogenous hKLRG1 overexpressed in Chinese hamster ovary (CHO)-K1 cells, but not in parental CHO-K1 cells, in immunocytochemistry. We next showed that both mAbs detected endogenous hKLRG1 expressed in human NK cells. These results demonstrate that KLMab-1 and recKLMab-1 are available for immunocytochemistry.","PeriodicalId":53514,"journal":{"name":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy","volume":" ","pages":"279-284"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40431679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broad Based Immunity? 广泛豁免?

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Pub Date : 2022-10-01 DOI: 10.1089/mab.2022.29010.editorial

Thomas Kieber-Emmons

引用次数: 0